demonstrated that IL-1 is associated with impaired T-cell responses in women with advanced epithelial ovarian cancer (121), suggesting that interleukins activated by NLRP3 may promote ovarian cancer progression by influencing immune responses. This evidence concerns the gene NLRP3 and ovarian carcinoma.